What is BMEA's current stock price?

BMEA (Biomea Fusion, Inc.) is currently trading at $1.42 with a market cap of $84.5M.

What sector is Biomea Fusion, Inc. in?

Biomea Fusion, Inc. (BMEA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is BMEA a good stock to buy?

Analysts have a Buy consensus on BMEA with a price target of $20.20. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

BMEA Biomea Fusion, Inc.

Healthcare

$1.42+3.65%ClosedMarket Cap: $84.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.48

P/S

0.00

EV/EBITDA

-0.65

DCF Value

$0.98

FCF Yield

-66.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-196.7%

ROA

-96.9%

ROIC

-173.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-12.4M	$—
Q4 null	$0.00	$4.6M	$—
FY null	$0.00	$-61.8M	$—
Q3 null	$0.00	$-16.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$20.20

Target (Median)

$19.00

Target Range

$10.00 - $40.00

2 Strong Buy5 Buy0 Hold0 Sell1 Strong Sell

D. Boral CapitalBuy

2026-04-28

CitigroupBuy

2026-03-27

D. Boral CapitalBuy

2026-03-25

D. Boral CapitalBuy

2026-01-13

CitigroupBuy

2025-11-10

Trading Activity

Insider Trades

View All

Hitchcock Michael J.M.director, officer: Interim CEO

SellFri Apr 03

Erdtmann Rainer Mdirector, officer: See Remarks

SellFri Apr 03

Erdtmann Rainer Mdirector, officer: See Remarks

SellFri Feb 06

Erdtmann Rainer Mdirector, officer: See Remarks

BuyMon Dec 15

Hitchcock Michael J.M.director, officer: Interim CEO

BuyThu Dec 04

Latest News

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific SessionsGlobeNewsWire · Tue May 05

Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes TranscriptSeeking Alpha · Tue Apr 28

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib TreatmentGlobeNewsWire · Mon Apr 27

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.34

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Peers